Previous findings indicate that reducing brain insulin-like growth factor I receptor (IGF-IR) activity promotes ample neuroprotection. We now examined a possible action of IGF-IR on brain glucose transport to explain its wide protective activity, as energy availability is crucial for healthy tissue function. Using 18 FGlucose PET we found that shRNA interference of IGF-IR in mouse somatosensory cortex significantly increased glucose uptake upon sensory stimulation. In vivo microscopy using astrocyte specific staining showed that after IGF-IR shRNA injection in somatosensory cortex, astrocytes displayed greater increases in glucose uptake as compared to astrocytes in the scramble-injected side. Further, mice with the IGF-IR knock down in astrocytes showed increased glucose uptake in somatosensory cortex upon sensory stimulation. Analysis of underlying mechanisms indicated that IGF-IR interacts with glucose transporter 1 (GLUT1), the main facilitative glucose transporter in astrocytes, through a mechanism involving interactions with the scaffolding protein GIPC and the multicargo transporter LRP1 to retain GLUT1 inside the cell. These findings identify IGF-IR as a key modulator of brain glucose metabolism through its inhibitory action on astrocytic GLUT1 activity.
Introduction
Reduction of brain IGF-IR activity provides salutary effects. Intriguingly, neuroprotective actions of lowered brain IGF-IR encompass a wide variety of insults of different etiology (Biondi et al. 2015; Cohen et al. 2009; De Magalhaes Filho et al. 2016; Gontier et al. 2015) , and even prolong lifespan (Kappeler et al., 2008) . While diverse mechanisms have been invoked to explain the ample spectrum of beneficial actions of reduced IGF-IR activity (Gazit et al. 2016; Kenyon 2010; Lopez-Otin et al. 2013; Vilchez et al. 2014) , it is possible that IGF-IR targets additional mechanisms of wide functional impact such as energy balance, as insulin-like receptors and their ligands are well known modulators of glucose and lipid handling in different tissues and species.
Conversely, IGF-I, the preferred ligand of IGF-IR, is generally considered a neuroprotective factor and has been proposed as a treatment for various neurodegenerative diseases (Fernandez and Torres-Aleman 2012) . This poses the paradox that either increasing IGF-I or reducing its receptor appears to lead to beneficial actions in the brain (Cohen and Dillin 2008; Fernandez and Torres-Aleman 2012) . While these apparently contradictory observations remain largely unexplained (but see (O'Neill et al., 2012) , one possibility is that IGF-IR has ligand independent actions, as recently reported for apoptotic signaling through insulin receptor (IR) and IGF-IR (Boucher et al., 2010) .
In the present work we analyzed a possible involvement of the IGF-I receptor on glucose handling by the brain, a key aspect in tissue homeostasis that could in theory form part of neuroprotection by insulin-like receptors, but remains little explored. We now describe that the IGF-I receptor inhibits in a ligand-independent manner the activity of glucose transporter 1 (GLUT1) in astrocytes, adding further support for a broad beneficial effect of reducing brain IGF-IR levels.
Materials and Methods

Animals
Adult ( ;hGFAP-CreERT2 mice. To excise loxP sites by Cre recombination, 6 weeks-old male mice were administrated a daily tamoxifen injection (10 mg/kg, intraperitoneal) for 5 days. Tamoxifen (Sigma) was dissolved in sunflower oil at a final concentration of 10 mg/ml at 37º, and then filter sterilized and stored for up to 7 days at 4ºC in the dark. IR loxP/loxP mice were used as controls and also were injected with tamoxifen. PCR genotyping was carried out using primer sets binding to Cre (Cre-1084, 5´-GCG GTC TGG   CAG TAA AAA CTA TC-3´; Cre-1085, 5´-GTG AAA CAG CAT TGC TGT CAC TT-3´ 
Plasmid Constructions and viral packaging
For viral transduction we used a three-plasmid system previously described (Dull et al. 1998 ).
The co-transfection system consisted of an shRNA plasmid against either IGF-IR or IR (also used for transfecting primary astrocyte cultures), a packaging construct (pCMV-dR8.2 Δvpr) and the vesicular stomatitis virus G-protein envelope (pMD2.G, Addgene, USA). shRNAs against Glut-1, IGF-IR, IR, scramble sequence and EGFP were from Origene (HuSH-29, Origene, USA): shRNA against GIPC was constructed as described in www.addgene.org/tools/protocols/plko/ using the primers: 5'CCGGACTCACCGA ACCTCGGAAGGCCTCGAGGCCTTCCGAGGTTCGGTGAGT TTTTTG3' and 5'AATTCAAAAAACTCACCGAACCTCGGAAGGCCTCGAGGCCTTCCGAGG TTCGGTGAGT3' directed against the 684-704 fragment of GIPC mRNA. The transfer vector (5 μg), the envelope (2 μg), and the packaging plasmids (5 μg) were co-transfected using calcium phosphate in human embryonic kidney 293 T cells (6 × 106 cells per dish) cultured in DMEM with 10% FCS and 1% penicillin/streptomycin. Lysosomal function was inhibited with cloroquine prior to transfection. The supernatant containing the viral particles was collected, filtered and stored at −80°C until use. Viral concentration was titrated as described (Munive et al. 2016) . Infection efficiency was ~80% as determined using GFP-expressing viral particles.
shLRP-1 was obtained as described (Nishijima et al. 2010 ). GLUT1-Exo Flag was a kind gift of JC Rathmell (Wieman et al. 2007 ).
Cell cultures and transfections
Astroglial cultures with >95% GFAP-positive cells were prepared as described (Fernandez et al. 2007) . Postnatal (day 3-4) brains from wild type, mutant As IGF-IR , and littermate mice were dissected and immersed in ice-cold Hank's balance salt solution (HBSS, Life Technologies, Spain). Cortex and hippocampus were removed and mechanically dissociated. The resulting cell suspension was centrifuged and plated in DMEM/F-12 (Life Technologies) with 10% fetal bovine serum (Life Technologies) and 100 mg/ml of antibiotic-antimycotic solution (SigmaAldrich). After 15-20 days, astrocytes were re-plated at 1.2×10 5 cells/well. For transfection, astrocytes were electroporated (2×10 6 astrocytes with 2 µg of plasmid DNA) before seeding using an astrocyte Nucleofector Kit (Amaxa, Lonza, Switzerland). After electroporation, cells were plated to obtain a final cell density on the day of the experiment similar to that obtained with the transfection method. The transfection efficiency was 60-80%, as assessed with a GFP vector.
Glucose assays
We used 6-NBDG to measure glucose transport in astrocytes as shown by others (Barros et al. 2009a ). Briefly, cells well starved in serum free media for 3 hours. Then IGF-I (PreProTec, UK), insulin (Sigma, USA), or vehicle were added to a final concentration of 1nM. We then added 6-NBDG (Setareh biotech, USA) to a final concentration of 30 µM. Cultures were kept for 3 hours at 37°C and then ice cold PBS was added and cells trypsinized. Cells were collected and FBS and PBS added. Fluorescence intensity was measured by flow cytometry (FACSAria cytometer, BD Biosciences, USA).
In Situ Proximity Ligation Assays (PLA)
GLUT1 -IGF-IR interactions were detected in astrocytes grown on glass coverslips using the Duolink II in situ PLA detection Kit (OLink; Bioscience, Sweden) as previously described (Gonzalez et al. 2012) . Astrocytes were fixed in 4% paraformaldehyde for 10 min, washed with PBS containing 20 mM glycine to quench the aldehyde groups, permeabilized with the same buffer containing 0.05% Triton X-100 for 5 min and successively washed with PBS. After 1 h/37°C with the blocking solution in a pre-heated humidity chamber, astrocytes were incubated overnight with primary antibodies: rabbit polyclonal anti-GLUT1 antibody (1:100, ref. 
Protein Translocation Assay
Translocation of GLUT1-Flag and IGF-IR to the cell membrane was evaluated following previously published procedures (Koshy et al. 2010 Universal PCR Master Mix according to the manufacturer's instructions (Life Technologies). All reactions were performed in a 7500 Real Time PCR system (Life Technologies). Quantitative real time PCR analysis was carried out as described (Pfaffl 2001) . Results were expressed as relative expression ratios on the basis of group means for target transcripts versus reference 18S
transcript. At least three independent experiments were done.
Lentiviral particles administration
Mice were anesthetized by inhalation of a mixture of isofluorane/oxygen (5% induction, 2% maintenance). After removing the duramater, the tip of the glass pipette was placed onto the surface of the brain. Two µl of lentiviral shRNA against IGF-I receptor (∼4x10 10 pfu/ml) were administered per mouse. Administration was made through a glass pipette connected to a
Hamilton syringe. Rate of infusion was 1µl per 10 min. Stereotaxical coordinates were -1.06mm
from bregma and -1mm lateral.
In vivo astrocyte glucose uptake
Glucose uptake by astrocytes was evaluated as previously described by others (Chuquet et al., 2010) according to the experimental set-up shown in Suppl Figure 1A , following procedures was applied to fix the coverslip. A light aluminum frame (2x3.5cm) with a central circular hole (10mm diameter) was attached to the skull centered on the craniotomy area and fixed with dental cement. The cranial frame was fixed to a heavy aluminum base. The base was moved to the imaging stage. The animals' body temperature was monitored during the procedure using a rectal probe (Technomed Europe, The Netherlands) and regulated using a heating pad (RS Amidata, Spain) controlled by a thermostat (Cibertec, Spain) set at 37°C.
6-NBDG administration
6-NBDG (Setareh biotech, USA) was dissolved in a solution of 55% of HEPES-ringed buffer and 45% of DMSO, pH 7.42, to a concentration of 5 mg/ml. A 300µl Hamilton syringe (Hamilton, USA) filled with the 6-NBDG solution was connected to the femoral artery cannula and placed in a micro-injector pump (Harvard Apparatus, USA). 6-NBDG was pumped at a rate of 20μl/min/100gr.
Stimulation Paradigm
The whiskers of the animal's snout were stimulated with 100 ms puffs of air produced at 5 Hz by a pressure injector (Dagan, USA) for 30 sec controlled by an Axon Digidata 1322A and pClamp software (Molecular Devices, USA). Air was ejected at 1 bar pressure via capillary glass, attached to plastic tubing, positioned ~1 cm lateral and anterior to the animal's nose to stimulate the whole left whisker pad. At the same time, tail pinching was performed at 2 Hz with steel forceps, providing a pairing protocol for astrocyte stimulation.
Laser Scanning Confocal Microscopy (LSCM)
Imaging was performed with a custom-built confocal laser (CVI Melles Griot, UK) scanning microscope consisting of an Olympus FV300 laser scanning confocal system coupled to an Olympus BX61WI upright microscope (Olympus, Japan) and a Olympus LUMPLFL 60XW/IR water immersion objective (0.9NA; Olympus)
Data analysis
Astrocytes were distinguished by using the red signal emitted by SR-101. Astrocytes concentrate SR-101, and their soma appear intensely bright (Nimmerjahn et al. 2004) . Each image of the sequence was aligned over the previous image with Align Slice (ImageJ, National
Institutes of Health, USA) to correct x-y deviation caused by possible drift of the tissue.
Fluorescence intensity was measured in a region of interest (ROI) strictly limited to the somatic area. Signals were expressed as relative fluorescence changes (ΔF/F0), where F0 was the mean of the baseline period. Astrocytes showing variations greater than 1 were considered as responders.
F-FDG PET imaging
18 F-FDG PET was used to measure brain glucose handling. Briefly, fasted mice were injected i.p. with the positron emitting radiotracer 18 F-FDG (18.5 MBq in 0.2 ml of 0.9% NaCl, Instituto
Tecnológico PET, Spain). During an uptake period of 45 min animals were anesthetized by inhalation of a mixture of isoflurane/oxygen (5% for induction and 2% for maintenance) and then placed on the bed of the tomograph. The duration of the PET acquisition was 20 min, immediately followed by a CT (computed tomography) scan. The scanner used was a specific small animal PET-CT hybrid tomograph (Albira ARS, Oncovision, Spain). After acquisition, PET images were reconstructed with an ordered subset expectation maximization (OSEM) algorithm, and with applied corrections for randoms, scatter, attenuation, dead time and radio element decay, whereas for the CT images a filtered back projection algorithm was used. For metabolic activity quantification, the procedure used was as follows: first, the CT image of the skull from each animal was co-registered to a magnetic resonance image (MRI) template of mouse brain in which the regions of interest (ROIs) were previously delineated. After the CT image was co-registered, the spatial mathematic transformation was saved and then applied to its own fused PET image, allowing the correct matching between the PET image and the MRI template. Once the 18 F-FDG uptake in the different brain regions was calculated (in kBq/cc units), the activity of each left hemisphere region was normalized to its homologous region in the right hemisphere and expressed as proportional uptake (left/right). All processes of visualization, co-registration and quantification were performed using PMOD 3.0 software (PMOD Technologies Ltd., Switzerland).
Statistics
Normal distribution tests were carried out in all initial set of experiments and a non- 
Results
IGF-IR in astrocytes modulates brain glucose uptake
We first examined whether IGF-IR affects brain glucose handling by reducing its levels with shRNA interference and measuring brain glucose uptake with 18 F fluoro-2 deoxy-glucose micro-PET imaging. A lentiviral vector expressing IGF-IR shRNA (Suppl Figure 1A) was stereotaxically injected into one side of the somatosensory cortex of wild type mice, whereas the contralateral side was injected with scrambled shRNA (Suppl Figure 1B ), using procedures already described in detail elsewhere (Carro et al. 2005) . After measuring baseline levels, we stimulated the whiskers bilaterally to increase glucose flux into the somatosensory cortex.
Whereas glucose uptake was increased in both sides after whisker stimulation (Suppl Figure 1C) , normalization of glucose levels in the side injected with IGF-IR shRNA with those in the scramble-injected side, both under basal conditions and after stimulation of the whiskers, revealed a significantly greater increase in glucose uptake after stimulation (Figure 1 ). No changes in glucose uptake were seen in a brain area such as the caudate-putamen that is not activated after whisker stimulation. Despite the limitations of PET analysis in small animals such as mice (Kuntner et al. 2009 ), these results indicate that reducing brain IGF-IR enhances brain glucose uptake in active brain regions.
Because it has been shown that astrocytes are the predominant type of cell involved in glucose uptake upon activation of the somatosensory cortex (Chuquet et al. 2010) , we used in vivo fluorescence microscopy (Suppl Figure 2) to visualize astrocytes in mice injected with IGF-IR shRNA in the somatosensory cortex, using procedures already described (Perez-Alvarez et al. Figure 3A) , even though total brain levels of IGF-IR were not significantly reduced in these mice, as many other brain cells express IGF-IR (Suppl Figure 3B ).
Opposing action of IR and IGF-IR on GLUT1 activity in astrocytes
We then examined mechanisms whereby IGF-IR reduces glucose transport using astrocyte cultures. We first confirmed that reduction of IGF-IR in shRNA IGF-IR-transfected astrocytes significantly increased glucose transport ( Figure 3A ). Because astrocytes also express IR (Suppl Figure 4A ), we also tested its role on glucose transport. Intriguingly, reduction of IR levels (Suppl Figure 4B ) decreased glucose transport in astrocytes ( Figure 3A ). Opposing actions of IR and IGF-IR on glucose transport were confirmed by the observation that when both receptors were reduced, the effects cancelled each other ( Figure 3A) . Modulation of basal glucose transport in astrocytes after reduction of either IR or IGF-IR reflects ligand-independent actions of these receptors (Boucher et al. 2010) , as experiments were conducted under serum-free conditions, and addition of either IGF-I or insulin in the presence or absence of the respective shRNAs did not alter glucose transport in any case (not shown).
Because GLUT1 is the main facilitative glucose transporter in astrocytes (Morgello et al. 1995) , we determined its role in IGF-IR and IR actions. We found that decreasing IR levels reduced GLUT1 mRNA ( Figure 3B ), resulting in decreased GLUT1 levels at the cell membrane ( Figure 3C ). Confirming these observations in vitro, we also found reduced levels of brain GLUT1 mRNA in mice lacking IR in astrocytes (GFAPIR-KO mice, Figure 3D ). Indeed, GFAPIR-KO mice show wide disturbances in brain glucose handling, as reported elsewhere (Garcia-Caceres et al, in press). Thus, astrocytic IR modulates GLUT1 expression, and consequently GLUT1 protein levels at the cell membrane are also affected. On the other hand, reduction of IGF-IR by shRNA did not affect GLUT1 mRNA levels ( Figure 3B ), but resulted in increased amounts of GLUT1 at the cell membrane of astrocytes, as determined by flow cytometry and membrane protein biotinylation ( Figure 3C ,E). The latter suggests that IGF-IR retains GLUT1 inside the cell and agrees with the observation that reduction of IGF-IR levels increases glucose transport in astrocytes.
We then started to determine possible underlying mechanisms. IGF-IR associates with GIPC (GAIP-interacting protein, C terminus) (Booth et al. 2002; Bunn et al. 1999 ), a scaffolding protein that participates in protein trafficking and binds to many partners, including GLUT1 (Bunn et al. 1999) . We hypothesized that GIPC may simultaneously interact with IGF-IR and GLUT1 through its PDZ domain because GIPC can dimerize (Katoh, 2013) . In support of this possibility we found that IGF-IR co-immunoprecipitates not only with GIPC, as already reported, but also with GLUT1, whereas GIPC, as expected, co-immunoprecipitates also with GLUT1 ( Figure 4A ). Proximity ligation assays (PLA) confirmed an interaction between IGF-IR and GLUT1 ( Figure 4B ). Significantly, neither GLUT1, or as previously shown (Ligensa et al. 2001 ), nor GIPC, co-immunoprecipitate with the insulin receptor ( Figure 4A ). To further establish a role of GIPC in the interaction between IGF-IR and GLUT1 we reduced GIPC levels in astrocytes using GIPC shRNA (Suppl Figure 4C ) and found that the interaction between IGF-IR and GLUT1 was significantly reduced ( Figure 4C ).
We examined a potential intermediary role of lipoprotein-receptor associated protein 1 (LRP1) in this mechanism as LRP1 is a multicargo membrane protein that associates to the IGF-I receptor in other type of brain cells (Nishijima et al., 2010) and is involved in GLUT translocation in neurons (Liu et al. 2015) . We confirmed that LRP1 and IGF-IR interact also in astrocytes (Suppl Figure 4D) , and that LRP1 is required for IGF-IR to interact with GLUT1 and GIPC as its reduction with shRNA (Suppl Figure 4E) reduces the amount of IGF-IR that immunoprecipitates with GLUT1 and GIPC ( Figure 4D ). No direct interaction of LRP1 with GLUT1 was observed (Suppl Figure 4F) .
Discussion
The present observations indicate that IGF-IR regulates glucose transporter 1 activity in astrocytes, impacting in this way on overall brain glucose transport. When IGF-IR levels are reduced, GLUT1 locates at the cell membrane and transports glucose inside the cell. Thus, unbound GLUT1 may contribute to basal glucose transport in astrocytes. Conversely, when GLUT1 is bound to IGF-IR, it remains inside the cell and associates to IGF-IR through proteinprotein interactions involving GIPC and LRP1 (see Summary Graphic). As a facilitative glucose transporter, GLUT1 takes up extracellular glucose in a concentration-dependent manner, which explains increased glucose transport in shRNA IGF-IR-injected mice receiving sensory stimulation. Indeed, local blood flow is increased in response to enhanced neuronal activity (Roy and Sherrington 1890) , and astrocytes, that fully wrap blood vessels (Mathiisen et al. 2010) , will take up more glucose through GLUT1. In turn, previous observations indicate that activitydependent modulation of astrocytic glucose transport relies on stimulation of GLUT1 by glutamate via engagement of the Na + -glutamate co-transporter and intracellular Na + -Ca ++ cosignaling (Loaiza et al. 2003; Porras et al. 2008) . Collectively, these observations provide additional information about the role of astrocytic GLUT1 in brain glucose metabolism.
In its IGF-IR-free state, GLUT1 is in the membrane and may be active. In this regard, and not withstanding different sensitivities of the methods used, the increase in glucose transport seen in astrocytes with reduced levels of IGF-IR is more robust that the increase seen in membrane GLUT1 levels. This could mean that the intrinsic activity of GLUT1, that can be regulated (Barnes et al. 2002) , is also affected by IGF-IR. Thus, when associated to IGF-IR, GLUT1 is retained inside the cell and its activity is down-regulated. Bound and unbound GLUT1 may constitute two separate pools in astrocytes. We also speculate that when bound to IGF-IR, GLUT1 may become subject to regulation by extracellular signals (glutamate…etc), but further work is needed.
This study confirms the utility of 6NBDG as a probe for glucose uptake, further supporting the notion that astrocytes are major contributors in glucose metabolism, as seen previously both in vivo (Chuquet et al. 2010) , and in different in vitro preparations (Barros et al. 2009b; Jakoby et al. 2014) . Importantly, both in anesthetized animals and in slices without anesthetics, 6NBDG
showed preferential astrocytic uptake. Another important aspect confirmed by our findings is that IR and IGF-IR display ligand-independent activities that may, or may not, be related to the actions of their ligands (Boucher et al., 2010) . In this regard, different authors have shown that IGF-I and insulin also affect glucose handling by astrocytes at different levels, including enhanced glucose uptake (Kum et al. 1992; Masters et al. 1991) and/or enhanced glycogen production (Dringen and Hamprecht 1992; Hamai et al. 1999; Muhic et al. 2015) . These observations suggest that insulin peptides and their receptors form an intricate glucose regulatory network in astrocytes that may even act in apparently opposing manners. Indeed, and through entirely different mechanisms, IGF-IR exerts an intrinsic inhibitory action on astrocytic glucose transport, while IR displays an intrinsic stimulatory activity. In this way, glucose uptake in astrocytes may in part be determined by a balance between IGF-IR and IR levels. This suggests that physiological and pathological processes impacting on astrocytic insulin and IGF-I receptor levels will influence glucose transport by the brain in opposite directions.
Collectively, these observations would help reconcile the apparent controversy on the role of these receptors and their ligands in the brain (Cohen and Dillin 2008) , which largely arises from studies in invertebrates harboring a single insulin-like receptor (Kenyon 2010) . Thus, while in C elegans a single insulin-like receptor is modulated by many different ligands, even in an antagonistic fashion (Matsunaga et al. 2012) , the acquisition of new insulin-like receptors in vertebrates has allowed the appearance of interactions among them. Based on present findings we consider that reported actions of insulin-like receptors in invertebrates should not be immediately inferred to be similar in vertebrates. The corollary of these observations is that invertebrate models of insulin-like receptor physiology in mammals should take into account the existence of two tyrosine kinase receptors, IGF-IR and IR, not present in invertebrates that may display cooperative (Boucher et al., 2010) or opposing activities (present observations), depending on biological context. Finally, since glucose transport by the brain deteriorates during aging and its associated pathologies (Mergenthaler et al. 2013 ), these observations provide further support for the use of strategies regulating brain IGF-IR levels to support healthy as well as pathological aging. Indeed, lowering IGF-IR in Alzheimer´s disease (AD) brains will not only diminish amyloidosis (Cohen et al. 2009 ), and related pathology such as hippocampal hyperactivity (Gazit et al. 2016 ), but will also likely contribute to normalize glucose dysregulation present as a characteristic alteration of this disease (La Joie et al. 2012) . Future work should examine major components of the IGF-IR pathway in astrocytes described herein for brain glucose regulation in experimental models of normal and pathological aging, as for example the recently described role of GLUT1 in AD (Winkler et al. 2015) . Altogether, these set of observations support a role of an interaction between insulin and IGF-I receptors in modulating glucose handling by astrocytes, adding a new layer of regulation by astrocytes of brain energy economy (Allaman et al. 2011) .
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LG Figure 1 Video. In response to whisker/tail stimulation, astrocytes (red) in somatosensory cortex increase glucose uptake (green). Stimulation is delivered at ∼9 sec in the video sequence. Astrocytes were stained with the specific astrocyte dye SR101 administered by intraperitoneal injection whereas glucose uptake was determined using the green fluorescent analog 6-NBDG delivered by intrafemoral artery injection.
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